SAB Biotherapeutics (SABS) Equity Average (2021 - 2026)

SAB Biotherapeutics has reported Equity Average for 6 years, with the latest figure at $189.4 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 699.42% year-over-year to $189.4 million; the trailing twelve-month figure through Mar 2026 stood at $189.4 million (up 699.42% YoY), and the FY2025 full-year result was $88.7 million, up 113.12% from the prior year.
• Equity Average for Q1 2026 stood at $189.4 million, up from $158.3 million in the prior quarter.
• The five-year high for Equity Average was $189.4 million in Q1 2026, with the low at $16.7 million in Q2 2025.
• Historically, Equity Average has averaged $53.0 million across 5 years, with a median of $36.3 million in 2023.
• Annual changes were most pronounced in 2025 — Equity Average sank 66.22% — and 2026, when it surged 699.42%.
• SAB Biotherapeutics' Equity Average stood at $30.8 million in 2022, then climbed by 17.63% to $36.3 million in 2023, then retreated by 13.35% to $31.4 million in 2024, then soared by 403.51% to $158.3 million in 2025, then advanced by 19.64% to $189.4 million in 2026.
• The last three Equity Average figures came in at $189.4 million (Q1 2026), $158.3 million (Q4 2025), and $88.5 million (Q3 2025), per Business Quant data.